In a market dominated by giants like Boston Scientific and Medtronic, Eximo Medical's Auryon System isn't just another peripheral atherectomy device—it's a calculated strike at the heart of procedural complexity. With zero organic traffic and a team of 12, they're building the future of vascular intervention without the noise.

"They're not chasing vanity metrics—they're building a billion-dollar medical device in stealth mode."

The Auryon System's promise—'Say goodbye to complicated'—isn't marketing fluff. In peripheral artery disease (PAD) treatment, where traditional atherectomy devices struggle with calcified lesions and procedural complexity, a system that simplifies the workflow while improving outcomes could command premium pricing and rapid adoption.

• Revenue concentration: $3M likely from a handful of early-adopter hospital systems
• Clinical evidence focus: Domain emphasizes 'science, technology, and clinical evidence' over flashy marketing
• Strategic silence: Zero organic traffic suggests private label sales or exclusive distribution agreements